RecruitingPhase 2NCT06667453
A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1
Studying Myotonic dystrophy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- PepGen Inc
- Intervention
- PGN-EDODM1(drug)
- Enrollment
- 24 enrolled
- Eligibility
- 16-60 years · All sexes
- Timeline
- 2024 – 2026
Study locations (8)
- University of Calgary, Calgary, Alberta, Canada
- Ottawa Hospital Research Institute (OHRI), Ottawa, Ontario, Canada
- CIUSSS du Saguenay-Lac-Saint-Jean, Chicoutimi, Quebec, Canada
- Montreal Neurological Institute, Montreal, Quebec, Canada
- Pacific Clinical Research Network Auckland, Takapuna, Auckland, New Zealand
- Salford Royal Hospital, Salford, England, United Kingdom
- University College London Hospitals NHS Foundation Trust, London, UK, United Kingdom
- Newcastle Upon Tyne Hospitals, Newcastle upon Tyne, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06667453 on ClinicalTrials.govOther trials for Myotonic dystrophy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07486934Efficacy, Safety, and Tolerability of DYNE-101 in Participants With Myotonic Dystrophy Type 1Dyne Therapeutics
- RECRUITINGPHASE2NCT07220603An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE)PepGen Inc
- ACTIVE NOT RECRUITINGNCT07493525Fall Frequency and Factors Affecting Dynamic Balance in Patients With Myotonic Dystrophy Type 1Antalya Training and Research Hospital
- RECRUITINGNCT06747884Trial Readiness and Endpoint Assessment in Pediatric Myotonic Dystrophy ExtensionVirginia Commonwealth University
- RECRUITINGNCT07385443The Spanish National Registry for Myotonic Dystrophy Type 1Fundació Institut Germans Trias i Pujol
- RECRUITINGNCT07362875Development of Quantitative Muscle Imaging as a Biomarker of Disease Endpoints in Myotonic DystrophyWake Forest University Health Sciences
- RECRUITINGNANCT06809049Music Intervention for Brain-Heart Disease in Myotonic Dystrophy Type 1 (DM1)Hanns Lochmuller
- RECRUITINGPHASE3NCT05532813Evaluation of the Efficacy and Safety of Metformin in the Myotonic Dystrophy Type 1 (Steinert's Disease)Assistance Publique - Hôpitaux de Paris